Financial Commitments and Contingencies and Key License Agreements - Narrative (Details)				1 Months Ended		3 Months Ended	9 Months Ended
	Jan. 01, 2022 USD ($)	Aug. 31, 2021 plaintiff	May 28, 2021 patent	Dec. 31, 2020 USD ($)	Apr. 30, 2018 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Long-term Purchase Commitment [Line Items]
Right-of-use asset obtained in exchange for operating lease liability						$ 400,000	$ 400,000
Facility and equipment under lease						1,869,000	1,869,000	$ 2,505,000
Accrued payroll and benefits						7,613,000	7,613,000	11,971,000
Deferred compensation liability, current and noncurrent						7,434,000	7,434,000	11,243,000
Bioverativ Therapeutics Inc., Subject Patents
Long-term Purchase Commitment [Line Items]
Number of patents allegedly infringed | patent			3
MD Anderson
Long-term Purchase Commitment [Line Items]
Achievement of regulatory milestones potential payments					$ 6,000,000
Payment of upfront fee					500,000
Potential payments based on achievement of sales milestones					$ 24,000,000
Chief Executive Officer
Long-term Purchase Commitment [Line Items]
Accrued payroll and benefits						2,600,000	2,600,000	3,100,000
Therapyx
Long-term Purchase Commitment [Line Items]
Potential payments based on additional achievements of regulatory milestones				$ 2,200,000
Asset purchase agreement, upfront payment				800,000
Potential payments based on worldwide annual net sales				167,500,000
Therapyx | I L12 Product
Long-term Purchase Commitment [Line Items]
Potential payments based on additional achievements of regulatory milestones				30,000,000
Therapyx | Each New Indication Approved
Long-term Purchase Commitment [Line Items]
Potential payments based on additional achievements of regulatory milestones				$ 2,500,000
Plaintiffs, Individual | Shareholder Litigation
Long-term Purchase Commitment [Line Items]
Number of plaintiffs | plaintiff		4
Entity Plaintiff | Shareholder Litigation
Long-term Purchase Commitment [Line Items]
Number of plaintiffs | plaintiff		1
ROLVEDON, Co-Development and Commercialization Agreement | Hanmi Pharmaceutical Co. Ltd. (“Hanmi”)
Long-term Purchase Commitment [Line Items]
Reduction in accrued liabilities	$ 11,200,000
Potential payments based on additional achievements of regulatory milestones	10,000,000
Rolvedon vs eflapegrastim						9,000,000	9,000,000
Poziotinib: In-License Agreement | Hanmi Pharmaceutical Co. Ltd. (“Hanmi”)
Long-term Purchase Commitment [Line Items]
Achievement of regulatory milestones potential payments	18,000,000
Supplemental royalty milestone limit	$ 15,000,000
Office and research facilities
Long-term Purchase Commitment [Line Items]
Facility and equipment under lease						1,500,000	1,500,000	2,100,000
Office equipment
Long-term Purchase Commitment [Line Items]
Facility and equipment under lease						$ 400,000	$ 400,000	$ 400,000
Minimum
Long-term Purchase Commitment [Line Items]
Remaining lease term						2 years	2 years
Maximum
Long-term Purchase Commitment [Line Items]
Remaining lease term						4 years	4 years